Elmar Kraus analyst DZ BANK

Currently out of the existing stock ratings of Elmar Kraus, 13 are a HOLD (39.39%), 20 are a BUY (60.61%).

Elmar Kraus

Work Performance Price Targets & Ratings Chart

Analyst Elmar Kraus, currently employed at DZ BANK, carries an average stock price target met ratio of 81.94% that have a potential upside of 22.48% achieved within 289 days.

Elmar Kraus’s has documented 66 price targets and ratings displayed on 12 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on GILD, Gilead Sciences at 13-Feb-2025.

Wall Street Analyst Elmar Kraus

Analyst best performing recommendations are on AZN (ASTRAZENECA PLC ADR).
The best stock recommendation documented was for AZN (ASTRAZENECA PLC ADR) at 2/11/2022. The price target of $124.66 was fulfilled within 46 days with a profit of $21.5 (20.84%) receiving and performance score of 4.53.

Average potential price target upside

BIIB Biogen LLY Eli Lilly and Company AZN AstraZeneca PLC ADR GILD Gilead Sciences AMGN Amgen ABBV AbbVie JNJ Johnson & Johnson MRK Merck mpany MDT Medtronic PLC SMMNY Siemens Healthineers AG ADR PFE Pfizer BMY Bristol-Myers Squibb Company

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 13-Feb-2025

$222

$22.85 (11.47%)

$224

5 days ago
(08-Jul-2026)

38/66 (57.58%)

$21.64 (10.80%)

321

Buy Since 04-Mar-2022

$242

$42.85 (21.52%)

$227

6 days ago
(07-Jul-2026)

48/83 (57.83%)

$36.3 (17.65%)

148

Buy Since 29-Jun-2026

$256

$56.85 (28.55%)

$255

14 days ago
(29-Jun-2026)

7/37 (18.92%)

$39.37 (18.17%)

256

Buy Since 28-Sep-2022

$221

$4.97 (2.30%)

$177

28 days ago
(15-Jun-2026)

24/40 (60%)

$22.36 (11.26%)

155

Buy Since 15-May-2026

$225

$8.97 (4.15%)

$214

1 months 28 days ago
(15-May-2026)

4/8 (50%)

$32.05 (16.61%)

54

Show more analysts

Please expand the browser size to see the chart

What Year was the first public recommendation made by Elmar Kraus?

On 2019

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?